What's Happening?
LEO Pharma has announced the FDA's acceptance of its supplemental New Drug Application for ANZUPGO® (delgocitinib) cream, aimed at treating chronic hand eczema in children aged 12-17. The application is supported by positive data from the DELTA TEEN trial,
which demonstrated the cream's efficacy and safety. If approved, ANZUPGO will be the first treatment specifically indicated for pediatric patients with moderate to severe chronic hand eczema, addressing a significant unmet medical need.
Why It's Important?
The approval of ANZUPGO for pediatric use would fill a critical gap in dermatological care, providing a targeted treatment for children suffering from chronic hand eczema. This condition can significantly impact quality of life, causing discomfort and interfering with daily activities. LEO Pharma's development of a non-steroidal treatment option reflects its commitment to advancing care for underserved patient populations, potentially improving outcomes and reducing reliance on corticosteroids.
What's Next?
Pending FDA approval, ANZUPGO could become a standard treatment for pediatric hand eczema, offering relief to many children and adolescents. LEO Pharma may continue to expand its research and development efforts, exploring additional applications for delgocitinib in other dermatological conditions. The company might also engage in educational initiatives to raise awareness about chronic hand eczema and the benefits of its new treatment.
